Structure of CC Chemokine Receptor 5 with a Potent Chemokine Antagonist Reveals Mechanisms of Chemokine Recognition and Molecular Mimicry by HIV

Immunity

Volumn 46, Issue 6, 2017, Pages 1005-1017.e5

  Zheng, Yi ^a   Han, Gye Won ^b   Abagyan, Ruben ^a   Wu, Beili ^c   Stevens, Raymond C ^b   Cherezov, Vadim ^b   Kufareva, Irina ^a   Handel, Tracy M ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

CCL5 RANTES; CCR5 gp120 interaction; Chemokine antagonist; G protein coupled receptor (GPCR); HIV entry inhibitor; maraviroc; membrane protein structure; two site model; V3 loop; viral mimicry

Indexed keywords

CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR5; EPITOPE; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CYCLOHEXANE DERIVATIVE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; MARAVIROC; PROTEIN BINDING; RANTES; TRIAZOLE DERIVATIVE;

ARTICLE; BINDING AFFINITY; CRYSTALLIZATION; HUMAN IMMUNODEFICIENCY VIRUS; HYDROPHOBICITY; MOLECULAR MIMICRY; MOLECULAR MODEL; MOLECULAR RECOGNITION; MOLECULE; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN STRUCTURE; ANIMAL; CHEMISTRY; DRUG EFFECTS; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; METABOLISM; MOLECULAR CLONING; PHYSIOLOGY; PROTEIN CONFORMATION; SF9 CELL LINE; SPODOPTERA; STRUCTURE ACTIVITY RELATION; VIRUS ENTRY; X RAY CRYSTALLOGRAPHY;

ANIMALS; CCR5 RECEPTOR ANTAGONISTS; CHEMOKINE CCL5; CLONING, MOLECULAR; CRYSTALLOGRAPHY, X-RAY; CYCLOHEXANES; HIV ENVELOPE PROTEIN GP120; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MODELS, MOLECULAR; MOLECULAR MIMICRY; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTORS, CCR5; SF9 CELLS; SPODOPTERA; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES; VIRUS INTERNALIZATION;

EID: 85028535161     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2017.05.002     Document Type: Article

References (68)

1. Abagyan, R., Totrov, M., Biased probability Monte Carlo conformational searches and electrostatic calculations for peptides and proteins. J. Mol. Biol. 235 (1994), 983–1002.
2. Adams, P.D., Afonine, P.V., Bunkóczi, G., Chen, V.B., Davis, I.W., Echols, N., Headd, J.J., Hung, L.-W., Kapral, G.J., Grosse-Kunstleve, R.W., et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66 (2010), 213–221.
3. Alexandrov, A.I., Mileni, M., Chien, E.Y.T., Hanson, M.A., Stevens, R.C., Microscale fluorescent thermal stability assay for membrane proteins. Structure 16 (2008), 351–359.
4. Ballesteros, J.A., Weinstein, H., Analysis and refinement of criteria for predicting the structure and relative orientations of transmembranal helical domains. Biophys. J. 62 (1992), 107–109.
5. Bannert, N., Craig, S., Farzan, M., Sogah, D., Santo, N.V., Choe, H., Sodroski, J., Sialylated O-glycans and sulfated tyrosines in the NH2-terminal domain of CC chemokine receptor 5 contribute to high affinity binding of chemokines. J. Exp. Med. 194 (2001), 1661–1673.
6. Blanpain, C., Doranz, B.J., Vakili, J., Rucker, J., Govaerts, C., Baik, S.S.W., Lorthioir, O., Migeotte, I., Libert, F., Baleux, F., et al. Multiple charged and aromatic residues in CCR5 amino-terminal domain are involved in high affinity binding of both chemokines and HIV-1 Env protein. J. Biol. Chem. 274 (1999), 34719–34727.
7. Burg, J.S., Ingram, J.R., Venkatakrishnan, A.J., Jude, K.M., Dukkipati, A., Feinberg, E.N., Angelini, A., Waghray, D., Dror, R.O., Ploegh, H.L., Garcia, K.C., Structural biology. Structural basis for chemokine recognition and activation of a viral G protein-coupled receptor. Science 347 (2015), 1113–1117.
8. Caffrey, M., Cherezov, V., Crystallizing membrane proteins using lipidic mesophases. Nat. Protoc. 4 (2009), 706–731.
9. Cerini, F., Gaertner, H., Madden, K., Tolstorukov, I., Brown, S., Laukens, B., Callewaert, N., Harner, J.C., Oommen, A.M., Harms, J.T., et al. A scalable low-cost cGMP process for clinical grade production of the HIV inhibitor 5P12-RANTES in Pichia pastoris. Protein Expr. Purif. 119 (2016), 1–10.
10. Cherezov, V., Hanson, M.A., Griffith, M.T., Hilgart, M.C., Sanishvili, R., Nagarajan, V., Stepanov, S., Fischetti, R.F., Kuhn, P., Stevens, R.C., Rastering strategy for screening and centring of microcrystal samples of human membrane proteins with a sub-10 microm size X-ray synchrotron beam. J. R. Soc. Interface 6:Suppl 5 (2009), S587–S597.
11. Chiu, J., Tillett, D., Dawes, I.W., March, P.E., Site-directed, Ligase-Independent Mutagenesis (SLIM) for highly efficient mutagenesis of plasmids greater than 8kb. J. Microbiol. Methods 73 (2008), 195–198.
12. Choi, W.-T., Nedellec, R., Coetzer, M., Colin, P., Lagane, B., Offord, R.E., Hartley, O., Mosier, D.E., CCR5 mutations distinguish N-terminal modifications of RANTES (CCL5) with agonist versus antagonist activity. J. Virol. 86 (2012), 10218–10220.
13. Cimbro, R., Peterson, F.C., Liu, Q., Guzzo, C., Zhang, P., Miao, H., Van Ryk, D., Ambroggio, X., Hurt, D.E., De Gioia, L., et al. Tyrosine-sulfated V2 peptides inhibit HIV-1 infection via coreceptor mimicry. EBioMedicine 10 (2016), 45–54.
14. Colin, P., Bénureau, Y., Staropoli, I., Wang, Y., Gonzalez, N., Alcami, J., Hartley, O., Brelot, A., Arenzana-Seisdedos, F., Lagane, B., HIV-1 exploits CCR5 conformational heterogeneity to escape inhibition by chemokines. Proc. Natl. Acad. Sci. USA 110 (2013), 9475–9480.
15. Cormier, E.G., Dragic, T., The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. J. Virol. 76 (2002), 8953–8957.
16. Cormier, E.G., Persuh, M., Thompson, D.A.D., Lin, S.W., Sakmar, T.P., Olson, W.C., Dragic, T., Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120. Proc. Natl. Acad. Sci. USA 97 (2000), 5762–5767.
17. Cormier, E.G., Tran, D.N., Yukhayeva, L., Olson, W.C., Dragic, T., Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes. J. Virol. 75 (2001), 5541–5549.
18. Dalton, J.A., Lans, I., Giraldo, J., Quantifying conformational changes in GPCRs: glimpse of a common functional mechanism. BMC Bioinformatics, 16, 2015, 124.
19. Doranz, B.J., Lu, Z.H., Rucker, J., Zhang, T.Y., Sharron, M., Cen, Y.H., Wang, Z.X., Guo, H.H., Du, J.G., Accavitti, M.A., et al. Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1. J. Virol. 71 (1997), 6305–6314.
20. Dorgham, K., Cerini, F., Gaertner, H., Melotti, A., Rossitto-Borlat, I., Gorochov, G., Hartley, O., Chapter Three - Generating Chemokine Analogs with Enhanced Pharmacological Properties Using Phage Display. Tracy, M.H., (eds.) Methods in Enzymology, 2016, Academic Press, 47–72.
21. Dragic, T., Trkola, A., Lin, S.W., Nagashima, K.A., Kajumo, F., Zhao, L., Olson, W.C., Wu, L., Mackay, C.R., Allaway, G.P., et al. Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry. J. Virol. 72 (1998), 279–285.
22. Duma, L., Häussinger, D., Rogowski, M., Lusso, P., Grzesiek, S., Recognition of RANTES by extracellular parts of the CCR5 receptor. J. Mol. Biol. 365 (2007), 1063–1075.
23. Emsley, P., Lohkamp, B., Scott, W.G., Cowtan, K., Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66 (2010), 486–501.
24. Farzan, M., Choe, H., Vaca, L., Martin, K., Sun, Y., Desjardins, E., Ruffing, N., Wu, L., Wyatt, R., Gerard, N., et al. A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5. J. Virol. 72 (1998), 1160–1164.
25. Fenalti, G., Giguere, P.M., Katritch, V., Huang, X.-P., Thompson, A.A., Cherezov, V., Roth, B.L., Stevens, R.C., Molecular control of δ-opioid receptor signalling. Nature 506 (2014), 191–196.
26. Gaertner, H., Cerini, F., Escola, J.-M., Kuenzi, G., Melotti, A., Offord, R., Rossitto-Borlat, I., Nedellec, R., Salkowitz, J., Gorochov, G., et al. Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide. Proc. Natl. Acad. Sci. USA 105 (2008), 17706–17711.
27. Garcia-Perez, J., Rueda, P., Alcami, J., Rognan, D., Arenzana-Seisdedos, F., Lagane, B., Kellenberger, E., Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5). J. Biol. Chem. 286 (2011), 33409–33421.
28. Hall, S.E., Mao, A., Nicolaidou, V., Finelli, M., Wise, E.L., Nedjai, B., Kanjanapangka, J., Harirchian, P., Chen, D., Selchau, V., et al. Elucidation of binding sites of dual antagonists in the human chemokine receptors CCR2 and CCR5. Mol. Pharmacol. 75 (2009), 1325–1336.
29. Hanes, M.S., Salanga, C.L., Chowdry, A.B., Comerford, I., McColl, S.R., Kufareva, I., Handel, T.M., Dual targeting of the chemokine receptors CXCR4 and ACKR3 with novel engineered chemokines. J. Biol. Chem. 290 (2015), 22385–22397.
30. Howard, O.M.Z., Shirakawa, A.-K., Turpin, J.A., Maynard, A., Tobin, G.J., Carrington, M., Oppenheim, J.J., Dean, M., Naturally occurring CCR5 extracellular and transmembrane domain variants affect HIV-1 Co-receptor and ligand binding function. J. Biol. Chem. 274 (1999), 16228–16234.
31. Huang, C.C., Lam, S.N., Acharya, P., Tang, M., Xiang, S.-H., Hussan, S.S., Stanfield, R.L., Robinson, J., Sodroski, J., Wilson, I.A., et al. Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science 317 (2007), 1930–1934.
32. Jin, J., Colin, P., Staropoli, I., Lima-Fernandes, E., Ferret, C., Demir, A., Rogée, S., Hartley, O., Randriamampita, C., Scott, M.G., et al. Targeting spare CC chemokine receptor 5 (CCR5) as a principle to inhibit HIV-1 entry. J. Biol. Chem. 289 (2014), 19042–19052.
33. Kabsch, W., XDS. Acta Crystallogr. D Biol. Crystallogr. 66 (2010), 125–132.
34. Kondru, R., Zhang, J., Ji, C., Mirzadegan, T., Rotstein, D., Sankuratri, S., Dioszegi, M., Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol. Pharmacol. 73 (2008), 789–800.
35. Krissinel, E., Henrick, K., Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372 (2007), 774–797.
36. Laurence, J.S., Blanpain, C., Burgner, J.W., Parmentier, M., LiWang, P.J., CC chemokine MIP-1 β can function as a monomer and depends on Phe13 for receptor binding. Biochemistry 39 (2000), 3401–3409.
37. Liu, W., Chun, E., Thompson, A.A., Chubukov, P., Xu, F., Katritch, V., Han, G.W., Roth, C.B., Heitman, L.H., IJzerman, A.P., et al. Structural basis for allosteric regulation of GPCRs by sodium ions. Science 337 (2012), 232–236.
38. Maeda, K., Das, D., Ogata-Aoki, H., Nakata, H., Miyakawa, T., Tojo, Y., Norman, R., Takaoka, Y., Ding, J., Arnold, G.F., et al. Structural and molecular interactions of CCR5 inhibitors with CCR5. J. Biol. Chem. 281 (2006), 12688–12698.
39. Martin, L., Blanpain, C., Garnier, P., Wittamer, V., Parmentier, M., Vita, C., Structural and functional analysis of the RANTES-glycosaminoglycans interactions. Biochemistry 40 (2001), 6303–6318.
40. Martin-Blondel, G., Brassat, D., Bauer, J., Lassmann, H., Liblau, R.S., CCR5 blockade for neuroinflammatory diseases–beyond control of HIV. Nat. Rev. Neurol. 12 (2016), 95–105.
41. McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C., Read, R.J., Phaser crystallographic software. J. Appl. Cryst. 40 (2007), 658–674.
42. Murshudov, G.N., Skubák, P., Lebedev, A.A., Pannu, N.S., Steiner, R.A., Nicholls, R.A., Winn, M.D., Long, F., Vagin, A.A., REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. D Biol. Crystallogr. 67 (2011), 355–367.
43. Navenot, J.-M., Wang, Z.X., Trent, J.O., Murray, J.L., Hu, Q.X., DeLeeuw, L., Moore, P.S., Chang, Y., Peiper, S.C., Molecular anatomy of CCR5 engagement by physiologic and viral chemokines and HIV-1 envelope glycoproteins: differences in primary structural requirements for RANTES, MIP-1 α, and vMIP-II Binding. J. Mol. Biol. 313 (2001), 1181–1193.
44. Nedellec, R., Coetzer, M., Lederman, M.M., Offord, R.E., Hartley, O., Mosier, D.E., Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor use. PLoS ONE, 6, 2011, e22020.
45. Pakianathan, D.R., Kuta, E.G., Artis, D.R., Skelton, N.J., Hébert, C.A., Distinct but overlapping epitopes for the interaction of a CC-chemokine with CCR1, CCR3 and CCR5. Biochemistry 36 (1997), 9642–9648.
46. Proudfoot, A.E.I., Power, C.A., Hoogewerf, A.J., Montjovent, M.-O., Borlat, F., Offord, R.E., Wells, T.N.C., Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J. Biol. Chem. 271 (1996), 2599–2603.
47. Proudfoot, A.E.I., Handel, T.M., Johnson, Z., Lau, E.K., LiWang, P., Clark-Lewis, I., Borlat, F., Wells, T.N., Kosco-Vilbois, M.H., Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc. Natl. Acad. Sci. USA 100 (2003), 1885–1890.
48. Qin, L., Kufareva, I., Holden, L.G., Wang, C., Zheng, Y., Zhao, C., Fenalti, G., Wu, H., Han, G.W., Cherezov, V., et al. Structural biology. Crystal structure of the chemokine receptor CXCR4 in complex with a viral chemokine. Science 347 (2015), 1117–1122.
49. Rabut, G.E., Konner, J.A., Kajumo, F., Moore, J.P., Dragic, T., Alanine substitutions of polar and nonpolar residues in the amino-terminal domain of CCR5 differently impair entry of macrophage- and dualtropic isolates of human immunodeficiency virus type 1. J. Virol. 72 (1998), 3464–3468.
50. Rizzuto, C., Sodroski, J., Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120. AIDS Res. Hum. Retroviruses 16 (2000), 741–749.
51. Rizzuto, C.D., Wyatt, R., Hernández-Ramos, N., Sun, Y., Kwong, P.D., Hendrickson, W.A., Sodroski, J., A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 280 (1998), 1949–1953.
52. Roche, M., Borm, K., Flynn, J.K., Lewin, S.R., Churchill, M.J., Gorry, P.R., Molecular Gymnastics: Mechanisms of HIV-1 Resistance to CCR5 Antagonists and Impact on Virus Phenotypes. Curr. Top. Med. Chem. 16 (2016), 1091–1106.
53. Scholten, D.J., Canals, M., Maussang, D., Roumen, L., Smit, M.J., Wijtmans, M., de Graaf, C., Vischer, H.F., Leurs, R., Pharmacological modulation of chemokine receptor function. Br. J. Pharmacol. 165 (2012), 1617–1643.
54. Simmons, G., Clapham, P.R., Picard, L., Offord, R.E., Rosenkilde, M.M., Schwartz, T.W., Buser, R., Wells, T.N., Proudfoot, A.E., Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 276 (1997), 276–279.
55. Steen, A., Larsen, O., Thiele, S., Rosenkilde, M.M., Biased and g protein-independent signaling of chemokine receptors. Front. Immunol., 5, 2014, 277.
56. Stepanov, S., Makarov, O., Hilgart, M., Pothineni, S.B., Urakhchin, A., Devarapalli, S., Yoder, D., Becker, M., Ogata, C., Sanishvili, R., et al. JBluIce-EPICS control system for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 67 (2011), 176–188.
57. Strong, M., Sawaya, M.R., Wang, S., Phillips, M., Cascio, D., Eisenberg, D., Toward the structural genomics of complexes: crystal structure of a PE/PPE protein complex from Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA 103 (2006), 8060–8065.
58. Swinney, D.C., Beavis, P., Chuang, K.T., Zheng, Y., Lee, I., Gee, P., Deval, J., Rotstein, D.M., Dioszegi, M., Ravendran, P., et al. A study of the molecular mechanism of binding kinetics and long residence times of human CCR5 receptor small molecule allosteric ligands. Br. J. Pharmacol. 171 (2014), 3364–3375.
59. Tam, K., Schultz, M., Reyes-Robles, T., Vanwalscappel, B., Horton, J., Alonzo, F. 3rd, Wu, B., Landau, N.R., Torres, V.J., Staphylococcus aureus Leukocidin LukED and HIV-1 gp120 Target Different Sequence Determinants on CCR5. MBio, 7, 2016, 7.
60. Tamamis, P., Floudas, C.A., Elucidating a key anti-HIV-1 and cancer-associated axis: the structure of CCL5 (Rantes) in complex with CCR5. Sci. Rep., 4, 2014, 5447.
61. Tan, Q., Zhu, Y., Li, J., Chen, Z., Han, G.W., Kufareva, I., Li, T., Ma, L., Fenalti, G., Li, J., et al. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science 341 (2013), 1387–1390.
62. Thiele, S., Steen, A., Jensen, P.C., Mokrosinski, J., Frimurer, T.M., Rosenkilde, M.M., Allosteric and orthosteric sites in CC chemokine receptor (CCR5), a chimeric receptor approach. J. Biol. Chem. 286 (2011), 37543–37554.
63. Tilton, J.C., Wilen, C.B., Didigu, C.A., Sinha, R., Harrison, J.E., Agrawal-Gamse, C., Henning, E.A., Bushman, F.D., Martin, J.N., Deeks, S.G., Doms, R.W., A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5. J. Virol. 84 (2010), 10863–10876.
64. Totrov, M., Abagyan, R., Protein-ligand docking as an energy optimization problem. Raffa, R.B., (eds.) Drug-Receptor Thermodynamics: Introduction and Applications, 2001, Wiley, 603–624.
65. Weitzenfeld, P., Ben-Baruch, A., The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer. Cancer Lett. 352 (2014), 36–53.
66. Wescott, M.P., Kufareva, I., Paes, C., Goodman, J.R., Thaker, Y., Puffer, B.A., Berdougo, E., Rucker, J.B., Handel, T.M., Doranz, B.J., Signal transmission through the CXC chemokine receptor 4 (CXCR4) transmembrane helices. Proc. Natl. Acad. Sci. USA 113 (2016), 9928–9933.
67. Winn, M.D., Ballard, C.C., Cowtan, K.D., Dodson, E.J., Emsley, P., Evans, P.R., Keegan, R.M., Krissinel, E.B., Leslie, A.G.W., McCoy, A., et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol. Crystallogr. 67 (2011), 235–242.
68. Zheng, Y., Qin, L., Zacarías, N.V., de Vries, H., Han, G.W., Gustavsson, M., Dabros, M., Zhao, C., Cherney, R.J., Carter, P., et al. Structure of CC chemokine receptor 2 with orthosteric and allosteric antagonists. Nature 540 (2016), 458–461.